Global Analysis for Polycystic Ovarian Syndrome (PCOS) Drugs Market and Forecast to 2020

Persistence Market Research is released new forthcoming report on title "Polycystic Ovarian Syndrome (PCOS) Drugs Market: Global Industry Analysis and Forecast to 2020".

Logo

New York, NY -- (SBWire) -- 11/12/2014 --Polycystic ovarian syndrome is a common hormonal endocrine disorder. It is also known as Stein-Leventhal Syndrome. It caused due to formation of cysts on the ovary and don’t form sufficient amount of hormone to initiate ovulation. Some of the symptoms of PCOS are irregular ovulation, polycystic ovaries, excessive facial hair growth, skin problems, thinning of hair on the scalp, high level of androgens in the body and irregular or no menstrual periods. The symptoms of PCOS are not related to each other, so the condition is usually overlooked or undiagnosed. The cause of polycystic ovarian syndrome is unknown. Excessive insulin and low grade inflammation are some of the factors which may lead to polycystic ovarian syndrome. There are no specific tests for the diagnosis of polycystic ovarian syndrome. Physical examination, medical history, blood tests, pelvic examination and vaginal ultrasound helps in diagnosis of polycystic ovarian syndrome. Early diagnosis and treatment can help to control the symptoms and prevent long term complications. Some of the complications associated with polycystic ovarian syndrome are sleep apnea, infertility, abnormal uterine bleeding, high blood pressure, uterine cancer, cholesterol and lipid abnormalities and type II diabetes. Treatment for PCOS is dependent on women’s age, symptoms and future pregnancy plans. Lifestyle modification, surgery and medications are some of the treatment for PCOS. Surgery is performed to increase the chances of ovulation. Treatment may also include acne treatment, tropical anti hair growth medication, birth control pills to regulate menstruation and insulin sensitizing medication. Spironolactone, metformin, oral contraceptives and eflornithine are some of the drugs used for the treatment of PCOS.

Buy Full Report:
http://www.persistencemarketresearch.com/market-research/polycystic-ovarian-syndrome-drugs-market.asp

North America dominates the global market for PCOS drugs due to high prevalence and huge demand for diagnosis and treatment for PCOS. Asia is expected to show high growth rates in the next five years in the global PCOS drugs market. China and India are expected to be the fastest growing PCOS drugs markets in Asia-Pacific region. Some of the key driving forces for PCOS drugs market in emerging countries are large pool of patients, rise in healthcare expenditure and rising government initiative by organizing awareness programs.

In recent times there is increased use of PCOS drugs due to increasing prevalence of polycystic ovarian syndrome. Increasing prevalence of diabetes, rise in obesity rate, increase in genetic and hormonal disorders and increased government funding are some of the key factors driving the growth for global PCOS drugs market. In addition, increasing healthcare awareness about women health is also fuelling the growth of global PCOS drugs market. However, lack of approved drugs and presence of large number of generic drugs are some of the major factors restraining the growth for global PCOS drugs market.

Increase in R&D investment for new drugs and pipeline drugs would develop opportunity for the global PCOS drugs market. Some of the major companies operating in the global PCOS drugs market are Sanofi SA, Bristol Myers Squibb Co, Novartis A.G., Catalysis S.L, Dexa Medica Group, Teva Pharmaceutical Inc, AstraZeneca plc, Crinetics Pharmaceuticals, Inc., Ferring Pharmaceuticals, Inc., Neurocrine Biosciences, Inc. and Merck & Co. Inc.

Request Full Toc:
http://www.persistencemarketresearch.com/toc/3682

About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Media Relations Contact

Glen Hare
Marketing Head
Persistence Market Research
646-568-7751
http://www.persistencemarketresearch.com/market-research/polycystic-ovarian-syndrome-drugs-market.asp

View this press release online at: http://rwire.com/561508